Current Problems of Psychiatry

Curr Probl Psychiatry 2010; 11(4): 291-293

Andrzej Czernikiewicz MD, Ph.D.

Chair of Department of Psychiatry at Medical University in Lublin, Poland

Abstract

Depression is a complex disease with some psychiatric comorbidities, especially anxiety disorders and some comorbid physical symptoms.During the past few years, there has been a strong interest in the development of dual-action antidepressants with a better side effect profile. There are interesting pharmacological reasons why an antidepressant that act on more that one neurotransmitter system might have superior efficacy than antidepressant with single action. There also is an increasing body of evidence for an efficacy advantage in some patients with selective dual-action antidepressants, especially in large group of patients with high manifestation of physical symptoms of depression. Dual-acting antidepressants that inhibit reuptake of both serotonin and norepinephrine (SNRIs) treat a wider array of depressive symptoms (psychological and physical) than antidepressants that target either neurotransmitter alone. SNRIs such as venlafaxine, and duloxetine, may have an earlier onset of action, superior remission abilities, and better efficacy in treating anxiety symptoms of depression than the SSRIs. The remission rates of the patients taking venlafaxine were significantly higher than those of the patients taking SSRIs, regardless of age or gender. Overall, dual-acting agents appear to be more effective than single-acting agents in improving mood, reducing pain, and increasing the chance of remission.

Keywords

antidepressants – SNRIs - SSRIs– treatment guidelines

References

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. APPI; Washington DC: 1994.
2. Kennedy S.H., Lam R.W., Nutt D.J., Thase M.E. Treat-ing depression effectively. Applying clinical guidelines. Martin Dunitz; London-New York: 2007.
3. Delgado P.L., Charney D.S., Price L.H., Aghajanian G.K., Landis H., Heninger G.R. Serotonin function and the me-chanism of antidepressant action: reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch. Gen. Psychiatry, 1990; 47: 411-418.
4. Miller H.L., Delgado P.L., Salomon R.M., Berman R., Krystal J.H., Heninger G.R., Charney D.S. Clinical and biochemical effects of catecholamine depletion on anti-depressant-induced remission of depression. Arch. Gen. Psychiatry, 1996; 53: 117-128.
5. Tran P., Bymaster F.P., McNamara R.K., Potter W.Z. Dual monoamine modulation for improved treatment of major de-pressive disorder. J. Clin. Psychopharmacol., 2003; 23: 78-86.
6. Thase M.E., Entsuah A.R., Rudolph R.L. Remission rates during treatment with venlafaxine or selective serotonin reup-take inhibitors. Br. J. Psychiatry, 2001; 178: 234-241.
7. Sindrup S.H., Jensen T.S. Efficacy of pharmacological treat-ments of neuropathic pain: an update and effect related to me-chanism of drug action. Pain, 1999; 88: 389-400.
8. Barkin R.L., Fawcett J. The management challenges of chronic pain: the role of antidepressants. Am. J. Ther., 2000; 7: 31-47.
9. Kunz N.R., Goli V., Entsuah R., et al. Diabetic neuropathic pain management with venlafaxine extended release. Eur. Neuropsychopharmacol., 2000; 10(suppl 3): S389.
10. Nelson J.C., Mazure C.M., Bowers M.B. Jr, Jatlow P.I. A preliminary, open study of the combination of fluoxe-tine and desipramine for rapid treatment of major depres-sion. Arch. Gen. Psychiatry, 1991; 48: 303-307.
11. Entsuah A.R., Huang H., Thase M.E. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. J. Clin. Psy-chiatry, 2001; 62: 869-877.
12. 12. Jain R Single-action versus dual-action antidepressants.